EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel Cannabinoid Receptor 2 (CB2) Low Lipophilicity Agonists Produce Distinct cAMP and Arrestin Signalling Kinetics without Bias

Raahul Sharma iD, Sameek Singh iD, Zak M Whiting iD, Maximilian Molitor iD, Andrea J Vernall iD, Natasha L Grimsey iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24076406 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Raahul Sharma und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auc…. Hauptthemen laut MEDLINE: Arrestin, Cyclohexanols. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Research Council of New Zealand, Royal Society of New Zealand, School of Medical Sciences, University of Auckland, New Zealand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cannabinoid Receptor 2 (CB2) is a promising target for treating inflammatory diseases. We designed derivatives of 3-carbamoyl-2-pyridone and 1,8-naphthyridin-2(1H)-one-3-carboxamide CB2-selective agonists with reduced lipophilicity. The new compounds were measured for their affinity (radioligand binding) and ability to elicit cyclic adenosine monophosphate (cAMP) signalling and β-arrestin-2 translocation with temporal resolution (BRET-based biosensors). For the 3-carbamoyl-2-pyridone derivatives, we found that modifying the previously reported compound UOSS77 (also known as S-777469) by appending a PEG2-alcohol via a 3-carbomylcyclohexyl carboxamide (UOSS75) lowered lipophilicity, and preserved binding affinity and signalling profile. The 1,8-naphthyridin-2(1H)-one-3-carboxamide UOMM18, containing a cis configuration at the 3-carboxamide cyclohexyl and with an alcohol on the 4-position of the cyclohexyl, had lower lipophilicity but similar CB2 affinity and biological activity to previously reported compounds of this class. Relative to CP55,940, the new compounds acted as partial agonists and did not exhibit signalling bias. Interestingly, while all compounds shared similar temporal trajectories for maximal efficacy, differing temporal trajectories for potency were observed. Consequently, when applied at sub-maximal concentrations, CP55,940 tended to elicit sustained (cAMP) or increasing (arrestin) responses, whereas responses to the new compounds tended to be transient (cAMP) or sustained (arrestin). In future studies, the compounds characterised here may be useful in elucidating the consequences of differential temporal signalling profiles on CB2-mediated physiological responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ArrestinCyclohexanolsSignal TransductionCyclic AMPPyridonesReceptors, CannabinoidReceptor, Cannabinoid, CB2Receptor, Cannabinoid, CB1Cannabinoid Receptor Agonists

Stichwörter der Autor:innen

CB2beta-arrestin 2cannabinoidcannabinoid receptor agonistschemistrycyclic AMPdrug developmentkineticspharmaceuticalreceptorsignal transduction

Substanzen

3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanolArrestinCyclohexanolsCyclic AMPPyridonesReceptors, CannabinoidReceptor, Cannabinoid, CB2Receptor, Cannabinoid, CB1Cannabinoid Receptor Agonists

Autor:innen und Institutionen

  • Department of Pharmacology and Clinical Pharmacology, School of Medical Sciences, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1023, New Zealand.
  • Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, Auckland 1023, New Zealand.
  • Department of Chemistry, University of Otago, Dunedin 9016, New Zealand.
  • Chemical Biology and Therapeutics Science, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
  • Institute of Pharmaceutical Chemistry, Goethe University, 60438 Frankfurt, Germany.
  • Maurice Wilkins Centre for Molecular Biodiscovery, Auckland 1142, New Zealand.

ORCID-Profile: Raahul Sharma, Sameek Singh, Zak M Whiting, Maximilian Molitor, Andrea J Vernall, Natasha L Grimsey

Förderung

  • Health Research Council of New Zealand
  • Royal Society of New Zealand
  • School of Medical Sciences, University of Auckland, New Zealand
  • Royal Society Te Apārangi New Zealand Marsden Fund Fast-Start Grant
  • School of Medical Sciences, University of Auckland

Zitieren

APA

Sharma, R., Singh, S., Whiting, Z. M., Molitor, M., Vernall, A. J., & Grimsey, N. L. (2023). Novel Cannabinoid Receptor 2 (CB2) Low Lipophilicity Agonists Produce Distinct cAMP and Arrestin Signalling Kinetics without Bias. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24076406

Vancouver

Sharma R, Singh S, Whiting ZM, Molitor M, Vernall AJ, Grimsey NL. Novel Cannabinoid Receptor 2 (CB2) Low Lipophilicity Agonists Produce Distinct cAMP and Arrestin Signalling Kinetics without Bias. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24076406

BibTeX
@article{Sharma2023,
  author = {Sharma, Raahul and Singh, Sameek and Whiting, Zak M and Molitor, Maximilian and Vernall, Andrea J and Grimsey, Natasha L},
  title = {Novel Cannabinoid Receptor 2 (CB2) Low Lipophilicity Agonists Produce Distinct cAMP and Arrestin Signalling Kinetics without Bias},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24076406}
}
Kostenlos starten →